How Does Zyflo Work? Mechanism of Action Explained in Plain English

Zyflo (zileuton) has a mechanism of action that no other FDA-approved medication shares. Understanding how it works isn't just an interesting pharmacology lesson — it explains why Zyflo may be the right choice for certain patients when other asthma medications have fallen short.

The Problem: What Goes Wrong in Asthma?

In asthma, your airways overreact to triggers like allergens, cold air, exercise, or aspirin (in AERD patients). When this happens, inflammatory cells in the lungs begin a chain reaction that leads to:

Airway inflammation — the airways swell and become red and irritated

Bronchoconstriction — the muscles around the airways tighten, narrowing the air passage

Mucus hypersecretion — the airways produce excess mucus, making it even harder to breathe

Key molecules driving this inflammation are called leukotrienes — specifically LTB4 (which recruits inflammatory cells) and the cysteinyl leukotrienes LTC4, LTD4, and LTE4 (which cause bronchoconstriction and mucus production). Leukotrienes are far more potent bronchoconstrictors than histamine — up to 1,000 times more potent, by some estimates.

Where Leukotrienes Come From: The 5-LOX Pathway

Leukotrienes are made from arachidonic acid — a fatty acid found in cell membranes. When your immune system is triggered (by an allergen, aspirin, exercise, or cold air), cell membranes release arachidonic acid, which then enters the 5-lipoxygenase (5-LOX) pathway.

The 5-LOX enzyme converts arachidonic acid into an intermediate called 5-HPETE, which is then further processed into all four major leukotrienes — LTB4, LTC4, LTD4, and LTE4. Think of 5-LOX as the factory where leukotrienes are manufactured. No 5-LOX activity = no leukotrienes.

How Zyflo Works: Shutting Down the Factory

Zyflo (zileuton) works by directly and selectively inhibiting the 5-lipoxygenase enzyme. By blocking 5-LOX, Zyflo prevents the first step of the leukotriene manufacturing process — cutting off the supply of leukotrienes before they are produced.

Both the R(+) and S(-) enantiomers of zileuton are pharmacologically active as 5-LOX inhibitors. Zileuton is a racemic mixture (50:50), meaning both molecular 'mirror images' contribute to the drug's effect.

The result: with 5-LOX inhibited, your body produces significantly less of all four major leukotrienes. Less LTC4, LTD4, and LTE4 means less bronchoconstriction and mucus. Less LTB4 means fewer neutrophils recruited to inflame your airways.

How Zyflo Differs from Montelukast and Zafirlukast

Montelukast (Singulair) and zafirlukast (Accolate) are leukotriene receptor antagonists (LTRAs). They do not block leukotriene production — they work downstream, at the receptor level. Here's the difference visualized:

Zyflo (zileuton): Blocks 5-LOX → prevents leukotriene production → all four leukotrienes are reduced

Montelukast/Zafirlukast: Leukotrienes are still produced → LTRAs block the cysteinyl leukotriene receptor (CysLT1) → LTC4, LTD4, LTE4 can't bind → reduced bronchoconstriction. But LTB4 (which uses a different receptor) is not blocked.

This matters clinically because:

Zyflo reduces LTB4 as well as cysteinyl leukotrienes — montelukast does not. LTB4 is a powerful recruiter of neutrophils to the lung, which plays a role in severe asthma and AERD.

Zyflo completely blocks leukotriene synthesis — LTRAs only block one type of receptor, and leukotrienes are still being produced.

For AERD patients, who have abnormally high leukotriene production as a core disease driver, stopping production (zileuton) may be more effective than blocking receptors (montelukast). Survey data show 28% of AERD patients rate zileuton as 'extremely effective' vs. 15% for montelukast.

Why Does Zileuton Require Liver Monitoring?

Zileuton is metabolized by the liver using cytochrome P450 enzymes CYP1A2, 2C9, and 3A4. It is also a weak inhibitor of CYP1A2. The drug and its metabolites can place stress on liver cells in susceptible individuals, leading to elevated liver enzymes in approximately 2% of patients. This is why baseline and periodic LFT monitoring is required during treatment.

Why Does Zileuton Interact With Theophylline, Propranolol, and Warfarin?

Because zileuton inhibits CYP1A2, it slows the metabolism of drugs processed by this enzyme. Theophylline is a major CYP1A2 substrate — when zileuton is added, theophylline clearance drops by ~50%, approximately doubling its blood levels. This interaction is clinically important and requires theophylline dose reduction. Propranolol and warfarin (R-isomer) are similarly affected.

The Pharmacokinetics: How Zileuton Moves Through Your Body

Zileuton is well-absorbed orally. It is metabolized in the liver by CYP1A2, 2C9, and 3A4, and its metabolites are eliminated primarily through the urine (~95%), with approximately 2% via feces. The extended-release formulation (Zyflo CR) uses a triple-layer tablet design with an immediate-release layer for rapid onset and an extended-release layer for sustained blood levels throughout the day. This design allows for the twice-daily dosing schedule.

See also: What Is Zyflo? Uses, Dosage, and What You Need to Know in 2026

See also: Zyflo Drug Interactions: What to Avoid and What to Tell Your Doctor